A 4-week vancomycin pulse and taper regimen may be a safe and effective strategy to delay or prevent Clostridioides difficile ...

Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors ...

A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections. Clinical trials showed Vowst significantly ...

The recent approval of the first oral fecal-derived microbiota therapy to prevent the recurrence of Clostridioides difficile (C. diff) infection in patients was welcome news for physicians who've ...

Researchers may not yet understand the mechanism behind recurrent Clostridium difficile infections, but they may have isolated five risk factors, according to a study published in Infection Control & ...

Please provide your email address to receive an email when new articles are posted on . Allegretti presented data at Digestive Disease Week on safety outcomes and concomitant medication changes after ...

Vowst is a prescription drug that’s used in adults to help prevent Clostridioides difficile (C. diff) infection from coming back after it has been treated. Vowst comes as an oral capsule. Vowst ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, now, it’s the source of gut infections that are tough to treat. About half a ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...